menu
    • menu
    [{"orgOrder":0,"company":"LadRx","sponsor":"XOMA","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Large molecule","year":"2023","type":"Financing","leadProduct":"AE-Keto-Sulf07","moa":"","graph1":"Oncology","graph2":"IND Enabling","graph3":"LadRx","amount2":0.01,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Oncology","amount2New":0.01,"dosageForm":"","sponsorNew":"LadRx \/ XOMA","highestDevelopmentStatusID":"5","companyTruncated":"LadRx \/ XOMA"},{"orgOrder":0,"company":"LadRx","sponsor":"XOMA","pharmaFlowCategory":"D","therapeuticArea":"Rare Diseases and Disorders","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Arimoclomol","moa":"","graph1":"Rare Diseases and Disorders","graph2":"Phase II\/ Phase III","graph3":"LadRx","amount2":0.059999999999999998,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Rare Diseases","amount2New":0.059999999999999998,"dosageForm":"Capsule","sponsorNew":"LadRx \/ XOMA","highestDevelopmentStatusID":"9","companyTruncated":"LadRx \/ XOMA"},{"orgOrder":0,"company":"LadRx","sponsor":"ImmunityBio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2024","type":"Termination","leadProduct":"Aldoxorubicin","moa":"","graph1":"Oncology","graph2":"Phase III","graph3":"LadRx","amount2":0.35999999999999999,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Oncology","amount2New":0.35999999999999999,"dosageForm":"Infusion","sponsorNew":"LadRx \/ ImmunityBio","highestDevelopmentStatusID":"10","companyTruncated":"LadRx \/ ImmunityBio"}]

    Find Clinical Drug Pipeline Developments & Deals by LadRx

    Menu

    LadRx

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            LadRx

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            LadRx

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aldoxorubicin

                            Therapeutic Area : Oncology

                            Study Phase : Phase III

                            Sponsor : ImmunityBio

                            Deal Size : $356.0 million

                            Deal Type : Termination

                            DEALS_DEV arrow-down

                            LadRx and ImmunityBio Mutually Agree to Terminate Aldoxorubicin License

                            Details : With the termination, LadRx regains control of INNO-206 (aldoxorubicin), a rationally-engineered cytotoxic which delivers well-established anti-cancer agent, doxorubicin, into the tumor.

                            Brand Name : INNO-206

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            June 03, 2024

                            Lead Product(s) : Aldoxorubicin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase III

                            Sponsor : ImmunityBio

                            Deal Size : $356.0 million

                            Deal Type : Termination

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            LadRx

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            LadRx

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Arimoclomol

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase II/ Phase III

                            Sponsor : XOMA

                            Deal Size : $58.6 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            FDA Accepts Zevra's Arimoclomol NDA for NPC Type C, Triggering Milestone Payment

                            Details : XOMA acquired royalty and milestone rights for LadRx Corporation’s BRX-345 (arimoclomol) for Niemann-Pick Disease Type C, and aldoxorubicin, an albumin-linked formulation of doxorubicin.

                            Brand Name : BRX-345

                            Molecule Type : Small molecule

                            Upfront Cash : $5.0 million

                            January 11, 2024

                            Lead Product(s) : Arimoclomol

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : XOMA

                            Deal Size : $58.6 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            LadRx

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            LadRx

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AE-Keto-Sulf07

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : XOMA

                            Deal Size : $11.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            LadRx Completes Non-Dilutive Financing Transaction for up to $11 Million with XOMA Corporation

                            Details : The Company expects to use the proceeds to advance its lead novel LADR-based anti-cancer drug, LADR-7 (AE-keto-sulf07) towards an IND filing with the FDA.

                            Brand Name : LADR7

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            June 22, 2023

                            Lead Product(s) : AE-Keto-Sulf07

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : XOMA

                            Deal Size : $11.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            LadRx

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed

                            LadRx

                            U.S.A arrow
                            Antibody Engineering
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Aldoxorubicin

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            LadRx Highlights Patent Issued for Its LADR Technology

                            Details : INNO-206 (aldoxorubicin) is a prodrug of doxorubicin that binds endogenous albumin after administration. The bound doxorubicin is released in the acidic environment of the tumor cell through cleavage of an acid sensitive linker and expresses antitumor ef...

                            Brand Name : INNO-206

                            Molecule Type :

                            Upfront Cash : Not Applicable

                            March 27, 2023

                            Lead Product(s) : Aldoxorubicin

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth